Cannabis Bioscience International Holdings ( (CBIH) ) has released a notification of late filing.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cannabis Bioscience International Holdings, Inc. has filed a Form 12b-25 to notify investors of a delay in submitting its Form 10-Q (Quarter Report) for the quarter ended November 30, 2025. The company states that the financial information required for this Form 10-Q (Quarter Report), covering the period ended August 31, 2025, could not be analyzed and finalized in time to meet the prescribed SEC deadline.
The delay is attributed to the company’s inability to complete its financial analysis and reporting process on schedule, suggesting internal timing and resource constraints rather than any disclosed external event such as an auditor change or regulatory inquiry. Management indicates that the issues could not be resolved without incurring unreasonable effort or expense within the original timeframe.
In line with SEC rules, Cannabis Bioscience expects to file the late Form 10-Q (Quarter Report) within the standard grace period—no later than five calendar days after the original due date. The company has affirmed that all other required periodic reports over the past 12 months have been filed on time, signaling that this is an isolated delay rather than part of a broader compliance pattern.
Preliminary figures point to a deterioration in the company’s operating performance. For the three months ended November 30, 2025, the loss from operations is estimated at about $96,000, compared with $59,627 a year earlier. Estimated revenues fell to roughly $53,000 from $74,248, and gross profit declined to about $43,000 from $66,445 over the same period. Total operating expenses rose to around $139,000 from $126,072, driven by higher general and administrative costs and professional fees, partially offset by lower contract labor and rent. The net loss for the quarter is expected to widen to about $109,000 from $79,528 in the prior-year quarter, reflecting both weaker operating results and higher interest costs.
The company cautions that these numbers are preliminary and remain subject to further review by management and its independent registered public accounting firm. As a result, the final figures presented in the forthcoming Form 10-Q (Quarter Report) for the period ended November 30, 2025, may differ, potentially significantly, from the estimates disclosed in the notification. Investors should treat these statements as forward-looking and recognize that actual results may vary once the review is complete.
Cannabis Bioscience emphasizes its intention to complete the reporting process and bring its SEC filings up to date within the allowed extension window. The Form 12b-25 notification has been signed on behalf of the company by Chief Executive Officer Dante Picazo, who also serves as the principal accounting officer, underscoring management’s direct involvement in addressing the delay and maintaining ongoing compliance with reporting requirements.
More about Cannabis Bioscience International Holdings
Cannabis Bioscience International Holdings, Inc. is a Houston, Texas–based company operating in the cannabis-related sector, focusing on bioscience-driven products and services. As a smaller reporting issuer, it generates modest quarterly revenues and continues to invest in general and administrative functions and professional services, which weigh on profitability.
Current Market Cap: $6.98M
Learn more about CBIH stock on TipRanks’ Stock Analysis page.